Colivelin vs FGL Peptide
Research Verdict
Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Quick Answers
Which is better, Colivelin or FGL Peptide?
Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
What is the key difference between Colivelin and FGL Peptide?
FGL peptide signals through FGFR1, a known oncogene pathway, raising theoretical long-term safety concerns absent from colivelin's ADNF/humanin mechanism.
Evidence Comparison
Neither has human trial data. Colivelin: rodent neuroprotection studies via ADNF/humanin pathways. FGL peptide: NCAM-derived, rodent-only data with FGFR1-mediated signaling. Evidence is comparably weak for both - Level D preclinical only.
Evidence Context Favoring Colivelin
Neuroprotection research targeting ADNF-humanin signaling without oncogenic pathway concerns.
Evidence Context Favoring FGL Peptide
NCAM-mediated neural plasticity research where FGFR1 engagement is mechanistically relevant, accepting the oncogene-pathway caveat.
Side-by-Side Snapshot
| Evidence grade | Colivelin: Level D FGL Peptide: Level D |
|---|---|
| Research status | Colivelin: Preclinical FGL Peptide: Preclinical |
| Primary category | Colivelin: Cognitive & Nootropic FGL Peptide: Cognitive & Nootropic |
| Cited studies | Colivelin: 2 FGL Peptide: 3 |